13.07
+0.17(+1.32%)
Currency In USD
| Previous Close | 12.9 |
| Open | 12.64 |
| Day High | 13.53 |
| Day Low | 12.57 |
| 52-Week High | 23.4 |
| 52-Week Low | 3.52 |
| Volume | 5.85M |
| Average Volume | 3.59M |
| Market Cap | 594.29M |
| PE | -12.81 |
| EPS | -1.02 |
| Moving Average 50 Days | 17.99 |
| Moving Average 200 Days | 8.97 |
| Change | 0.17 |
If you invested $1000 in Capricor Therapeutics, Inc. (CAPR) 10 years ago, it would be worth $384.41 as of December 21, 2024 at a share price of $13.07. Whereas If you bought $1000 worth of Capricor Therapeutics, Inc. (CAPR) shares 5 years ago, it would be worth $11,365.22 as of December 21, 2024 at a share price of $13.07.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Capricor Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Dec 02, 2024 9:15 PM GMT
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is schedul
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
GlobeNewswire Inc.
Nov 20, 2024 2:00 PM GMT
Milestone represents a significant step forward in the development of deramiocel for the treatment of Duchenne muscular dystrophy in the European regionSAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnolo
Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting
GlobeNewswire Inc.
Nov 12, 2024 2:00 PM GMT
-Abstract Highlights New Preclinical Data on Exosome-Based Delivery of PMOs for the Treatment of DMD-SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exoso